Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 15/20 | 0.71 |
| ▸ | AKR1C2 | P52895 | 15/20 | 0.71 |
| ▸ | CTSV | O60911 | 3/20 | 0.64 |
| ▸ | CTSL | P07711 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415572 | 0.89 | AKR1C3 (0.82) | AKR1C3AKR1C2CTSVCTSLMEN1 | |
| SCHEMBL14598928 | 0.88 | AKR1C3 (0.71) | AKR1C3AKR1C2CTSVCTSLMEN1 | |
| SCHEMBL14598923 | 0.85 | AKR1C3 (0.78) | AKR1C3AKR1C2CTSVCTSLMEN1 | |
| SCHEMBL6801970 | 0.85 | AKR1C3 (0.73) | AKR1C3AKR1C2CTSVCTSLMEN1 | |
| SCHEMBL31500240 | 0.84 | AKR1C3 (0.69) | AKR1C3AKR1C2CTSVCTSLMEN1 | |
| SCHEMBL8773601 | 0.84 | AKR1C3 (0.81) | AKR1C3AKR1C2CTSVCTSLMEN1 | |
| SCHEMBL14598926 | 0.84 | AKR1C3 (0.81) | AKR1C3AKR1C2CTSVCTSLMEN1 | |
| SCHEMBL9593627 | 0.83 | MEN1 (0.83) | AKR1C3AKR1C2CTSVCTSLMEN1 | |
| SCHEMBL9595058 | 0.83 | AKR1C3 (1.00) | AKR1C3AKR1C2MEN1LMNAKMT2A | |
| SCHEMBL6801722 | 0.83 | CTSV (0.60) | AKR1C3AKR1C2CTSVCTSLMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825199-B2 | 7-Substituted quinazolin-2,4-diones useful as antibacterial agents | WARNER-LAMBERT COMPANY | 2004-11-30 | — | — | US | disclosed |
| EP-1028950-B1 | 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER LAMBERT CO (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | DOMAGALA JOHN MICHAEL (US) | 2002-08-22 | — | — | US | disclosed |
| US-6331538-B1 | TREATMENT OF BACTERIAL INFECTION | WARNER-LAMBERT COMPANY | 2001-12-18 | — | — | US | disclosed |
| EP-1028950-A1 | NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999021840-A1 | NOVEL 7-SUBSTITUTED QUINAZOLIN-2,4-DIONES USEFUL AS ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY (US) | 1999-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115674-A1 | Novel 7-substituted quinazolin-2,4-diones useful as antibacterial agents | NQO2, TOP1, TOP2A | AKR1C3 4233/4885AKR1C2 4195/4885CTSV 1587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.